Full-year EBITDA margin target of ~23%
Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets.
CIPLA / guidance tracker
Keep management guidance in view.
Cipla · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
Symbicort filing by end of FY24
Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023.
4-5 peptide launches in next two years
Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period.
Advair launch within 12 months via de-risking
Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.
EBITDA margin guidance of 24.5%-25.5% for FY25
Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.
U.S. sustainable quarterly run rate of $235-240 million
Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.
Two peptide launches expected in H2 FY25
Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.
Advair filing by end of 2024, potential launch in H1 CY2025
ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
FY26 EBITDA margin guidance maintained at 23.5%-24.5%
Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments.
US revenue target of ~$1 billion by FY27
CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
India branded business to grow in line with IPM in next three quarters
COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
Biosimilar launch in US expected in Q2 FY26
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
EBITDA margin guidance raised to 23-24% for FY24
Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end.
Generic Symbicort filing in Q3 FY24
Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies.
Peptide product launch in Q4 FY24
One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.
US revenue sustainable range of $220-225M next quarter
Management guided US revenue of $220-225M as sustainable for the next quarter.
EBITDA margin guidance maintained at 24.5%-25.5% for FY25
Management reiterated full-year EBITDA margin guidance despite Q2 margin of 26.7%, expecting normalized Q3 and Q4.
Generic Advair launch expected in H1 FY2026
Risking of generic Advair progressing as per expectations; launch targeted for first half of fiscal 2026.
Lanreotide supply issues to resolve by end of Q3, recovery in Q4
Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25.
One India to outpace market growth on full-year basis
Management expects India business to revert to growth trajectory with respiratory uptick in Q3 and outpace market growth for the full year.
FY26 EBITDA margin guidance revised to 22.75%-24%
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
Launch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
US revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
FY24 EBITDA margin at higher end of 23-24%
Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%.
Advair filing by mid-FY25
Advair generic expected to be filed by mid-FY25 from an alternate site, with approval likely by end of next fiscal.
Four peptide launches in FY25
Four peptide launches planned in FY25, with one asset awaiting approval expected in Q1 FY25.
Symbicort filing completed
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
FY26 top-line growth guidance retained
Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.
Generic Advair launch in late H1 FY26
Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.
Abraxane launch in H2 FY26
Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).
FY25 EBITDA margin to exceed guidance
EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
FY26 EBITDA margin guidance revised to ~21%
Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
U.S. launches: 4 respiratory and 4 peptide assets in FY27
Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
Lanreotide resupply expected in H1 FY27
Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
FY27 guidance to be provided next quarter
Management will provide FY27 guidance after finalizing the annual operating plan.
FY25 EBITDA margin guidance of 24.5%-25.5%
Management expects EBITDA margin expansion of up to 100 bps over FY24's 24.5%, driven by cost measures and portfolio mix.
Capex of INR 1,500 crore in FY25
Capital investments planned to enhance manufacturing capability and sustainability.
North America revenue growth aspiration for FY25
Aim to grow top line YoY, backed by commercial execution of existing portfolio and new launches.
Launch of 4 peptide assets in FY25
Targeting to launch four peptide assets during the fiscal year.
FY26 EBITDA margin guidance of 23.5%-24.5%
Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.
Advair launch expected in FY26
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Two to three peptide launches in FY26
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
U.S. revenue run rate of ~$220 million for Q1 FY26
Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
FY27 EBITDA margin guidance of 18.5-20%
Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
US business to reach $1B run-rate by FY27-end
Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.
India business to deliver double-digit growth in FY27-28
Management expects strong double-digit and market-beating growth in India for FY27 and FY28.
R&D spend to remain around 7% of sales
R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.